{"id":69584,"date":"2026-07-08T14:04:14","date_gmt":"2026-07-08T06:04:14","guid":{"rendered":"https:\/\/flcube.com\/?p=69584"},"modified":"2026-07-08T14:04:15","modified_gmt":"2026-07-08T06:04:15","slug":"ltz-therapeutics-secures-fda-ind-approval-for-ltz-232-first-in-class-myeloid-engager-targeting-epcam-high-solid-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69584","title":{"rendered":"LTZ Therapeutics Secures FDA IND Approval for LTZ-232, First-in-Class Myeloid Engager Targeting EpCAM-High Solid Tumors"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>LTZ Therapeutics<\/strong> announced that its second drug candidate, <strong>LTZ-232<\/strong>, has received <strong>Investigational New Drug (IND) approval<\/strong> from the <strong>U.S. Food and Drug Administration (FDA)<\/strong> for the treatment of <strong>advanced metastatic colorectal cancer (mCRC)<\/strong> and other <strong>EpCAM-high solid tumors<\/strong>. The molecule represents a <strong>first-in-class bispecific antibody<\/strong> leveraging the company&#8217;s proprietary <strong>U-MCE (Universal Myeloid Cell Engager) platform<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone-amp-development-status\" class=\"wp-block-heading\">Regulatory Milestone &amp; Development Status<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>LTZ Therapeutics<\/td><\/tr><tr><td><strong>Drug Candidate<\/strong><\/td><td>LTZ-232<\/td><\/tr><tr><td><strong>Regulatory Action<\/strong><\/td><td>FDA IND approval<\/td><\/tr><tr><td><strong>Indications<\/strong><\/td><td>Advanced metastatic colorectal cancer (mCRC)<br>Other solid tumors with high EpCAM expression<\/td><\/tr><tr><td><strong>Technology Platform<\/strong><\/td><td>U-MCE (Universal Myeloid Cell Engager)<\/td><\/tr><tr><td><strong>Molecule Type<\/strong><\/td><td>First-in-class bispecific antibody<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>7 July 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-mechanism-of-action-amp-therapeutic-innovation\" class=\"wp-block-heading\">Mechanism of Action &amp; Therapeutic Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Myeloid Engager Immunotherapy<\/strong>: LTZ-232 operates by <strong>precisely engaging tumor-associated macrophages (TAMs)<\/strong> with <strong>EpCAM-high tumor cells<\/strong>, activating the <strong>phagocytic function of macrophages<\/strong> to directly eliminate tumor cells through innate immune mechanisms.<\/li>\n\n\n\n<li><strong>Dual-Targeting Precision<\/strong>: The bispecific antibody simultaneously binds <strong>EpCAM (epithelial cell adhesion molecule)<\/strong> on tumor cells and specific receptors on TAMs, creating a targeted bridge that redirects macrophage activity specifically toward malignant cells while sparing healthy tissue.<\/li>\n\n\n\n<li><strong>Overcoming Resistance<\/strong>: By harnessing innate immunity rather than adaptive T-cell responses, LTZ-232 may provide therapeutic benefit in tumors resistant to current checkpoint inhibitors and T-cell engagers.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">EpCAM is overexpressed in <strong>80-90% of colorectal cancers<\/strong> and numerous other epithelial malignancies, representing a broad patient population with significant unmet need despite existing standard-of-care therapies.<\/p>\n\n\n\n<h2 id=\"h-platform-technology-amp-competitive-differentiation\" class=\"wp-block-heading\">Platform Technology &amp; Competitive Differentiation<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>U-MCE Platform<\/strong>: LTZ&#8217;s proprietary <strong>Universal Myeloid Cell Engager<\/strong> technology enables rational design of bispecific antibodies that specifically activate myeloid lineage immune cells, including macrophages, monocytes, and dendritic cells, expanding beyond the T-cell focused approaches dominating current immunotherapy development.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>First-in-Class Potential<\/strong>: LTZ-232 appears to be the <strong>first clinical-stage myeloid engager<\/strong> specifically targeting the EpCAM pathway, positioning LTZ at the forefront of next-generation innate immune oncology therapeutics.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Pipeline Strategy<\/strong>: As the company&#8217;s <strong>second clinical candidate<\/strong>, LTZ-232 validates the versatility of the U-MCE platform across multiple tumor targets and myeloid cell subtypes.<\/p>\n\n\n\n<h2 id=\"h-clinical-amp-commercial-outlook\" class=\"wp-block-heading\">Clinical &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Trial Design<\/strong>: Initial Phase I\/II studies will focus on dose escalation, safety, and preliminary efficacy in heavily pre-treated mCRC patients with confirmed EpCAM-high tumor expression.<\/li>\n\n\n\n<li><strong>Market Opportunity<\/strong>: Metastatic colorectal cancer represents a <strong>$5+ billion global market<\/strong> with limited effective options in later lines of therapy, creating significant commercial potential for novel mechanisms of action.<\/li>\n\n\n\n<li><strong>Combination Potential<\/strong>: Preclinical data suggest synergistic effects when combined with standard chemotherapy, anti-angiogenic agents, or immune checkpoint inhibitors, potentially enabling rapid advancement into combination regimens.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking information regarding clinical development, regulatory approvals, and market opportunities. Actual results may differ due to clinical trial outcomes, regulatory decisions, manufacturing challenges, and competitive developments.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>LTZ Therapeutics announced that its second drug candidate, LTZ-232, has received Investigational New Drug (IND)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[16,62,458,4850,25],"class_list":["post-69584","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-ltz-therapeutics","tag-myeloid-cell-engager","tag-potential-first-in-class"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>LTZ Therapeutics Secures FDA IND Approval for LTZ-232, First-in-Class Myeloid Engager Targeting EpCAM-High Solid Tumors - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"LTZ Therapeutics announced that its second drug candidate, LTZ-232, has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for the treatment of advanced metastatic colorectal cancer (mCRC) and other EpCAM-high solid tumors. The molecule represents a first-in-class bispecific antibody leveraging the company&#039;s proprietary U-MCE (Universal Myeloid Cell Engager) platform.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69584\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LTZ Therapeutics Secures FDA IND Approval for LTZ-232, First-in-Class Myeloid Engager Targeting EpCAM-High Solid Tumors\" \/>\n<meta property=\"og:description\" content=\"LTZ Therapeutics announced that its second drug candidate, LTZ-232, has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for the treatment of advanced metastatic colorectal cancer (mCRC) and other EpCAM-high solid tumors. The molecule represents a first-in-class bispecific antibody leveraging the company&#039;s proprietary U-MCE (Universal Myeloid Cell Engager) platform.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69584\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-08T06:04:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-08T06:04:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69584#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69584\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"LTZ Therapeutics Secures FDA IND Approval for LTZ-232, First-in-Class Myeloid Engager Targeting EpCAM-High Solid Tumors\",\"datePublished\":\"2026-07-08T06:04:14+00:00\",\"dateModified\":\"2026-07-08T06:04:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69584\"},\"wordCount\":457,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"LTZ Therapeutics\",\"Myeloid Cell Engager\",\"Potential first-in-class\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69584#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69584\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69584\",\"name\":\"LTZ Therapeutics Secures FDA IND Approval for LTZ-232, First-in-Class Myeloid Engager Targeting EpCAM-High Solid Tumors - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-08T06:04:14+00:00\",\"dateModified\":\"2026-07-08T06:04:15+00:00\",\"description\":\"LTZ Therapeutics announced that its second drug candidate, LTZ-232, has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for the treatment of advanced metastatic colorectal cancer (mCRC) and other EpCAM-high solid tumors. The molecule represents a first-in-class bispecific antibody leveraging the company's proprietary U-MCE (Universal Myeloid Cell Engager) platform.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69584#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69584\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69584#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LTZ Therapeutics Secures FDA IND Approval for LTZ-232, First-in-Class Myeloid Engager Targeting EpCAM-High Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"LTZ Therapeutics Secures FDA IND Approval for LTZ-232, First-in-Class Myeloid Engager Targeting EpCAM-High Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","description":"LTZ Therapeutics announced that its second drug candidate, LTZ-232, has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for the treatment of advanced metastatic colorectal cancer (mCRC) and other EpCAM-high solid tumors. The molecule represents a first-in-class bispecific antibody leveraging the company's proprietary U-MCE (Universal Myeloid Cell Engager) platform.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69584","og_locale":"en_US","og_type":"article","og_title":"LTZ Therapeutics Secures FDA IND Approval for LTZ-232, First-in-Class Myeloid Engager Targeting EpCAM-High Solid Tumors","og_description":"LTZ Therapeutics announced that its second drug candidate, LTZ-232, has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for the treatment of advanced metastatic colorectal cancer (mCRC) and other EpCAM-high solid tumors. The molecule represents a first-in-class bispecific antibody leveraging the company's proprietary U-MCE (Universal Myeloid Cell Engager) platform.","og_url":"https:\/\/flcube.com\/?p=69584","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-08T06:04:14+00:00","article_modified_time":"2026-07-08T06:04:15+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69584#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69584"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"LTZ Therapeutics Secures FDA IND Approval for LTZ-232, First-in-Class Myeloid Engager Targeting EpCAM-High Solid Tumors","datePublished":"2026-07-08T06:04:14+00:00","dateModified":"2026-07-08T06:04:15+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69584"},"wordCount":457,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Clinical trial approval \/ initiation","LTZ Therapeutics","Myeloid Cell Engager","Potential first-in-class"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69584#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69584","url":"https:\/\/flcube.com\/?p=69584","name":"LTZ Therapeutics Secures FDA IND Approval for LTZ-232, First-in-Class Myeloid Engager Targeting EpCAM-High Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-08T06:04:14+00:00","dateModified":"2026-07-08T06:04:15+00:00","description":"LTZ Therapeutics announced that its second drug candidate, LTZ-232, has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for the treatment of advanced metastatic colorectal cancer (mCRC) and other EpCAM-high solid tumors. The molecule represents a first-in-class bispecific antibody leveraging the company's proprietary U-MCE (Universal Myeloid Cell Engager) platform.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69584#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69584"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69584#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"LTZ Therapeutics Secures FDA IND Approval for LTZ-232, First-in-Class Myeloid Engager Targeting EpCAM-High Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69584","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69584"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69584\/revisions"}],"predecessor-version":[{"id":69585,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69584\/revisions\/69585"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69584"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69584"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69584"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}